Chrysafis Andreou

Dr. Chrysafis Andreou

Department of Electrical and Computer Engineering, University of Cyprus, 1678 Nicosia, Cyprus
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2013 in ACS Nano
Verified
Journal Article
Closed access
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
MHMehran R. Hoonejani
Mehran R. Hoonejani
MBMeysam R. Barmi
Meysam R. Barmi
MMMartin Moskovits
Martin Moskovits
CMCarl D. Meinhart
Carl D. Meinhart

15 November 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CKCharalambos Kaittanis
Charalambos Kaittanis
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
HHHaley Hieronymus
Haley Hieronymus
NMNinghui Mao
Ninghui Mao
CFCatherine A. Foss
Catherine A. Foss
JGJan Grimm
Jan Grimm
Prostate-specific membrane antigen (PSMA) or folate hydrolase 1 (FOLH1) is highly expressed on prostate cancer. Its expression correlates inversely with survival and increases with tumor grade. However, the biological role of PSMA has not been explored, and its role in prostate cancer remained elusive. Filling this gap, we demonstrate that in prostate cancer, PSMA initiates signaling upstream of PI3K through G protein–coupled receptors, specifically via the metabotropic glutamate receptor (mGluR). PSMA’s carboxypeptidase activity releases glutamate from vitamin B9 and other glutamated substrates, which activate mGluR I. Activated mGluR I subsequently induces activation of phosphoinositide 3-kinase (PI3K) through phosphorylation of p110β independent of PTEN loss. The p110β isoform of PI3K plays a particularly important role in the pathogenesis of prostate cancer, but the origin of its activation was so far unknown. PSMA expression correlated with PI3K–Akt signaling in cells, animal models, and patients. We interrogated the activity of the PSMA–PI3K axis through positron emission tomography and magnetic resonance imaging. Inhibition of PSMA in preclinical models inhibited PI3K signaling and promoted tumor regression. Our data present a novel oncogenic signaling role of PSMA that can be exploited for therapy and interrogated with imaging.

10 May 2016 in ACS Nano
Verified
Journal Article
Closed access
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
VNVolker Neuschmelting
Volker Neuschmelting
DTDarjus-Felix Tschaharganeh
Darjus-Felix Tschaharganeh
CHChun-Hao Huang
Chun-Hao Huang
AOAnton Oseledchyk
Anton Oseledchyk
MKMoritz F. Kircher
Moritz F. Kircher

1 January 2019 in Theranostics
Verified
Journal Article
Open access
FNFay Nicolson
Fay Nicolson
BABohdan Andreiuk
Bohdan Andreiuk
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
HHHsiao-Ting Hsu
Hsiao-Ting Hsu
SRScott Rudder
Scott Rudder
MKMoritz F. Kircher
Moritz F. Kircher
Rationale: The goal of imaging tumors at depth with high sensitivity and specificity represents a significant challenge in the field of biomedical optical imaging. 'Surface enhanced Raman scattering' (SERS) nanoparticles (NPs) have been employed as image contrast agents and can be used to specifically target cells in vivo. By tracking their unique “fingerprint” spectra, it becomes possible to determine their precise location. However, while the detection of SERS NPs is very sensitive and specific, conventional Raman spectroscopy imaging devices are limited in their inability to probe through tissue depths of more than a few millimetres, due to scattering and absorption of photons by biological tissues. Here, we combine the use of "Spatially Offset Raman spectroscopy" (SORS) with that of "surface-enhanced resonance Raman spectroscopy" (SERRS) in a technique known as "surface enhanced spatially offset resonance Raman spectroscopy" (SESO(R)RS) to image deep-seated glioblastoma multiforme (GBM) tumors in vivo in mice through the intact skull.

4 January 2017 in ACS Nano
Verified
Journal Article
Closed access
AOAnton Oseledchyk
Anton Oseledchyk
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
MWMatthew A. Wall
Matthew A. Wall
MKMoritz F. Kircher
Moritz F. Kircher

27 May 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Chrysafis AndreouChrysafis Andreou
Chrysafis Andreou
RWRalph Weissleder
Ralph Weissleder
MKMoritz F. Kircher
Moritz F. Kircher